Antimicrobial Resistance Channel launched

The Antimicrobial Resistance Channel – uniting the four pillars of AMR research

PLOS, in collaboration with the Global Antibiotic Research and Development Partnership (GARDP), is delighted to launch the Antimicrobial Resistance (AMR) Channel. This new Channel offers the AMR research community access to the latest research, as well as commentaries, blogs, news and discussions that span science, research and development, public health, and policy in the fight against AMR.

Antimicrobial Resistance is a serious threat to global public health that requires action across all sectors and society. Despite the international attention directed at AMR, and many policy discussions for developing new antibiotics accessible to all, the situation remains a major global concern. Key challenges include improving infection prevention, limiting unnecessary use of antibiotics, and using existing antibiotics appropriately in humans, animals, and in agriculture.

The PLOS AMR Channel is a resource for the AMR community to discover, explore and keep up to date with the latest scientific literature, commentaries, blogs, and news. Channel Editors comprise leading experts who will collate content to increase awareness of the AMR crisis, encourage research collaboration that integrates science, policy and public health, as well as highlight critical content in the fight against AMR. A holistic approach to research is urgently needed to provide the evidence-base for well-informed policy-making, governance, and funding.

Siloed research will not be effective in addressing AMR. The PLOS AMR Channel will highlight four pillars of AMR research (Basic Science – biology of disease, Research and Development, Appropriate Use and Access, Public Health – surveillance and epidemiology), but the Channel Editors are united in the belief that a coordinated, integrated, and prioritised research agenda is required to effectively ensure these areas form a singular public health response. The AMR Channel provides a space where these fields are brought together in one platform, and challenges researchers to think beyond individual research domains.

“Developing new treatments to tackle AMR is an important global priority. However, doing so in isolation of stewardship, access and surveillance jeopardizes the public health return on investment of developing accessible treatments,’ says Dr Manica Balasegaram, Director of GARDP and one of the Channel Editors. He continues ‘It’s important to move away from working in silos and find ways of bringing together the latest science, policy and public health research if we are to successfully address the challenges in AMR.”

The Four Pillars of Antimicrobial Resistance

Basic science – the biology of disease

Advances in the basic scientific understanding of microbes and host responses that are relevant to the discovery of new treatments including antibiotics are key to the battle against AMR. Finding new microbial targets that are druggable, emphasizing the interface between chemistry and biology, is especially important.

Channel Editor: Patricia Bradford

Deputy Channel Editor: Laura Piddock

Research and Development (R&D)

R&D into new treatments and health tools is not happening fast enough. Incentives to develop new antibiotics are slowly being introduced, but the deliverables are often poorly aligned with clinical needs. New diagnostic tools are needed to quickly and accurately identify the cause of infection and/or whether antibiotics are required. Ideally, these should be usable in areas with poor access to electricity and laboratory expertise.  Such tools will help optimise treatment and reduce wasteful empirical use.

Channel Editor: Manica Balasegaram

Deputy Channel Editor: Ursula Theuretzbacher

Appropriate use and Access

Overuse and misuse of antibiotics in humans and in animals coupled with poor infection control are the main drivers for the development and spread of AMR. Antimicrobial stewardship, originally applied as initiatives in hospitals to promote more appropriate antibiotic use, has now become a term for actions in all levels of society that promote responsible antibiotic use. There is a great need for globally agreed ‘rules of the game’ to set the stage for both responsible use of existing antibiotics and for the introduction of new ones. This also includes a better understanding on when and how use of antibiotics in animals affects resistance in microbes that cause infections in humans, and how this can be managed.

Channel Editor: Peter Beyer

Deputy Channel Editor: Ingrid Smith

Public health – Surveillance and epidemiology

Decision-making in effectively addressing AMR is driven by timely and accurate information. Gathering data on the emergence and spread of antibiotic resistance is important. However, simply monitoring or surveilling AMR without implementing interventions to reduce AMR will not be helpful in the long run. Surveillance, although incomplete for some countries, has already revealed that antimicrobial resistance is a global threat affecting rich and poor countries. Surveillance outcomes can be used in a rationale for changes in societal investment; for instance to determine whether specific treatments are productive when measured against improvements in QALYs (quality-adjusted life years). This is also where public health needs and priorities must inform R&D of health tools.

Channel Editor: Iruka Okeke

Deputy Channel Editor: Carmem Pessoa-Silva

The four pillars of AMR research require concerted and integrated action. Working in silos will be ineffective if we are to maintain life-saving antimicrobial medicines. Global approaches across all sectors are required. The goal of the PLOS AMR Channel is to break down these silos and facilitate collaboration and coordination to respond to this global health threat.

Check out the PLOS Antimicrobial Resistance Channel: channels.plos.org/amr


Source: PLOS Blogs

To subscribe to the Weekly Newsletter of new posts, enter your email here:


By PLOS

Published: May 24, 2018, 6:27 p.m.

Last updated: May 24, 2018, 6:28 p.m.

Print Share